Karex Berhad (5247) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Karex Berhad stock MYR 0.20, price MYR 0.41, that is 51.2% below the price, quality 50 out of 100. Rating: strongly overvalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range 0.3196 MYR – 1.05 MYR · fair‑value band 0.1600 MYR – 0.2400 MYR · the 0.4100 MYR price screens above the 0.2000 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 7, 2026.
Follow Karex Berhad in your weekly email
Every Wednesday you see whether Karex Berhad is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Karex Berhad, an investment holding company, manufactures and sells condoms in Malaysia. The company provides personal lubricants; probe covers; and catheters for transurethral drainage of the urinary bladder, as well as gloves. It also offers hand sanitizer and pre-vulcanised latex products.
Show moreShow less
In addition, the company engages in wholesale healthcare product related business. Karex Berhad operates in the Americas, Asia, Europe, and Africa. Karex Berhad serves brand owners, governments, non-governmental organizations, and retail purchasers.
The company was founded in 1988 and is based in Port Klang, Malaysia.
Stock analysis
Karex Berhad (5247) currently trades at 0.4100 MYR, while our model-based Fair Value estimate is 0.2000 MYR, 51% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 0.2800 MYR per share, and 1 of the 19 models we run sit above the 0.4100 MYR price.
Bear case: the Earnings-Based group reads lowest at 0.0700 MYR, and 18 of the 19 models stay below the price. Data coverage for this calculation is low.
Scenario range: 0.1600 MYR (bear) to 0.2400 MYR (bull), the price of 0.4100 MYR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Consumer Defensive sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Karex Berhad reported revenue of 462M MYR in FY2026 versus 422M MYR in FY2022, a compound +2.3%/yr. Reported net income was 291K MYR in FY2026.
Key figures
Market cap 432M MYR (≈ $106M) Micro · P/S ratio 0.93 · Dividend yield 2.4% · Net margin 0.1% · Return on equity 0.1% · Return on assets (EBIT) 2.1% (5-year average) · Operating margin 10.0% · Revenue (TTM) 462M MYR.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 53% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −26% fair-value upside, at −51%, 5247 screens richer than that median.
Fair Value models
Bear0.1600 MYRFair Value 0.2000 MYRBull0.2400 MYR
Price 0.4100 MYR · Downside -51.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−7.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.0%
Start year 2021 (pandemic). Over 10 years: +3.0% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.0%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in MYR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in MYR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +6.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year≈ +4.0%
Dividend (yield on the price)2.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.base effect: 4.0% / −41.9%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.1% → 2%
⚠ Base effect: the rate starts in the earnings trough around 2021 (starting value 0.000 per share, median 0.019 in 2016 to 2019). It measures the recovery from the trough, not lasting growth.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+31.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (Malaysia: IMF forecast 2.0% a year to 2030, 1.8% from 2016 to 2025) that is about +28.6% a year for the price and +6.7% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 230 stocks
Beats the industry median on 3/13 measures
Overall it trails its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside−51.2% · Bottom 25%
Profitability
Return on equity (12 months)0.1% · Below median
Return on assets0.0% · Bottom 25%
Net margin (12 months)0.1% · Below median
Operating margin (12 months)10.0% · Above median
Growth and dividend
Revenue growth (quarter YoY)−16.2% · Bottom 25%
Dividend yield (12 months)2.4% · Below median
Balance sheet
Debt / equity0.08× · Above median
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Karex Berhad Fair Value". https://www.fairvalue-calculator.com/stock/5247
Frequently asked questions
Is Karex Berhad (5247) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 0.2000 MYR versus a price of 0.4100 MYR, about 51% lower (overvalued).
What is the fair value of 5247?
Our model-based fair value for Karex Berhad is 0.2000 MYR (as of Nov 7, 2026), built from audited fundamentals. The current price: 0.4100 MYR.
What is the quality score of 5247?
Karex Berhad has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Karex Berhad (5247)?
Our model-based price target is the fair value of 0.2000 MYR (as of Nov 7, 2026) from 23 valuation models. Cautious scenario 0.1600 MYR, optimistic scenario 0.2400 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the Karex Berhad stock forecast for 2026?
Our models put fair value at 0.2000 MYR, about 51% lower versus a price of 0.4100 MYR (overvalued). Cautious scenario 0.1600 MYR, optimistic scenario 0.2400 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of Karex Berhad (5247)?
Karex Berhad reported trailing-twelve-month revenue of about 462M MYR (latest available figure, as of Nov 7, 2026).
Does Karex Berhad pay a dividend?
Karex Berhad currently shows a dividend yield of 2.44% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Karex Berhad (5247) and when is the ex-dividend date?
Karex Berhad pays a dividend of 0.01 MYR per share a year, a dividend yield of 2.4%. The last ex-dividend date was Sep 10, 2026. Free cash flow covers the dividend 1.30 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Karex Berhad (5247)?
For today's price to be fair in a discounted-cash-flow model, Karex Berhad would have to grow free cash flow by +31.1 % per year for five years (discount rate 12.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.0 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of 5247 use?
Our models discount Karex Berhad at 12.7 %: a base by market capitalisation (micro), damped by beta 0.62, country premium for Malaysia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Karex Berhad that is +31.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.7 %) and the same formula as our fair value.
How much growth has Karex Berhad (5247) delivered so far?
Over the past 5 years revenue at Karex Berhad grew +2.0 % a year. The price currently implies free-cash-flow growth of +31.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Karex Berhad (5247) growing?
The median revenue growth in the sector is +3.6 % a year. That is the yardstick for the growth priced into Karex Berhad (+31.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Karex Berhad (5247)?
The free-cash-flow yield on the price is 3.17 %: that much free cash flow Karex Berhad produces per unit of market value. When it exceeds the discount rate of our models (12.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Karex Berhad (5247)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Karex Berhad it is 0.2000 MYR per share (as of Nov 7, 2026), against a price of 0.4100 MYR. It is the blended result of 23 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Karex Berhad stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 5247 trades above its calculated fair value: price 0.4100 MYR, fair value 0.2000 MYR, a gap of about −51% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 5247?
No. The price is what the market pays today (0.4100 MYR); the fair value is what the company's own numbers justify (0.2000 MYR). For Karex Berhad the two are 0.2100 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is Karex Berhad worth?
The market values Karex Berhad at about 432M MYR (market capitalisation, as of Nov 7, 2026). Per share that is 0.4100 MYR; our models calculate a fair value of 0.2000 MYR per share.
What do the bullish and bearish scenarios say about 5247?
Our models span a range for Karex Berhad: cautious scenario 0.1600 MYR, base 0.2000 MYR, optimistic 0.2400 MYR per share (as of Nov 7, 2026, price 0.4100 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Karex Berhad (5247)?
Balance-sheet figures for Karex Berhad (as of Nov 7, 2026): return on equity 0.1%, debt of 0.08 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 5247 from its 52-week high?
Karex Berhad trades at 0.4100 MYR, about 53% below its 52-week high of 0.8640 MYR and 4% above the low of 0.3950 MYR (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 0.2000 MYR is for.
Which stocks are comparable to Karex Berhad?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, The Estée Lauder Companies Inc, Henkel AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Karex Berhad stock attractive at the current price?
The data as of Nov 7, 2026: price 0.4100 MYR, calculated fair value 0.2000 MYR (−51%), Quality Score 50/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 5247 calculated?
We run Karex Berhad through 23 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 0.2000 MYR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Karex Berhad itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Karex Berhad (5247)?
The closing price on Nov 6, 2026 was 0.4100 MYR. Our model-based fair value is 0.2000 MYR, about 51% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Karex Berhad right now?
The price sits above even our optimistic bull case (0.2400 MYR). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Karex Berhad (5247) come from?
Earnings per share at Karex Berhad grew −19.3 % a year from 2015 to 2026. Broken into its drivers: revenue per share +3.5 %, EBIT margin −15.7 %, tax rate −0.8 %, residual (interest, one-offs) −6.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Karex Berhad
How large is the market capitalisation of Karex Berhad (5247)?
The market capitalisation of Karex Berhad is 432M MYR (≈ $106M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Karex Berhad (5247)?
The price-to-sales ratio of Karex Berhad is 0.93 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Karex Berhad (5247)?
The dividend yield of Karex Berhad is 2.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Karex Berhad (5247)?
The net margin of Karex Berhad is 0.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Karex Berhad (5247)?
The return on equity (ROE) of Karex Berhad is 0.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Karex Berhad (5247)?
On an EBIT basis the return on assets of Karex Berhad is 2.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Karex Berhad (5247)?
The operating margin of Karex Berhad is 10.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Karex Berhad (5247)?
Revenue at Karex Berhad is growing −16.2% versus a year earlier (3y avg −4.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Karex Berhad (5247)?
Earnings per share at Karex Berhad are growing +236% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Karex Berhad (5247) carry?
The net debt of Karex Berhad is 192M MYR (fiscal year 2026, ≈ 14.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Karex Berhad in the live analysis
One click puts Karex Berhad on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026